Table 5.
Associations between methylation subtypes and biochemical recurrence (BCR) or metastatic-lethal events. Cause-specific Cox proportional hazards regression models are used. In the base models, BCR is adjusted for age and race; the metastatic-lethal events models are adjusted for age. In the full models, BCR is adjusted for age, race, Gleason score, PSA, and tumor stage; metastatic-lethal events are adjusted for age, Gleason score, PSA, and tumor stage. (a) TCGA-PRAD, results of metastatic-lethal events are not shown due to the limited sample size. (b) FH, (c) Canadian ICGC.
| a) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Base model |
Full model |
||||||||||
| No. patients (No. events) | HR (95% CI) | p-value | Global p-valuea |
No. patients (No. events) | HR (95% CI) | p-value | Global p-valuea |
||||
| BCR | |||||||||||
| Subtype 1 | 137(16) | REF | 134(16) | REF | |||||||
| Subtype 2 | 143(28) | 1.59 (0.86–2.95) | 0.14 | 137(27) | 1.55 (0.83–2.91) | 0.17 | |||||
| Subtype 3 | 109(23) | 1.89 (0.98–3.62) | 0.057 | 0.07 | 101(22) | 1.40 (0.72–2.74) | 0.32 | 0.25 | |||
| Subtype 4 | 86(21) | 2.09 (1.08–4.03) | 0.029 | 82(18) | 1.47 (0.73–2.98) | 0.28 | |||||
|
| |||||||||||
| b) | |||||||||||
|
| |||||||||||
| Base model |
Full model |
||||||||||
| No. patients (No. events) | HR (95% CI) | p-value | Global p-valuea |
No. patients (No. events) | HR (95% CI) | p-value | Global p-valuea |
||||
|
|
|||||||||||
| BCR | |||||||||||
| Subtype 1 | 123(26) | REF | 114(25) | REF | |||||||
| Subtype 2 | 210(65) | 1.44 (0.91–2.29) | 0.12 | 199(59) | 1.14 (0.71–1.86) | 0.57 | |||||
| Subtype 3 | 97(38) | 1.80 (1.09–2.99) | 0.03 | 0.007 | 90(37) | 1.09 (0.64–1.86) | 0.75 | 0.36 | |||
| Subtype 4 | 28(14) | 2.76 (1.43–5.31) | 0.002 | 27(14) | 1.41 (0.70–2.82) | 0.33 | |||||
| Metastatic-lethal | |||||||||||
| Subtype 1 | 100(3) | REF | 91(2) | REF | |||||||
| Subtype 2 | 156(11) | 2.19 (0.60–7.94) | 0.23 | 149(9) | 2.06 (0.43–9.80) | 0.36 | |||||
| Subtype 3 | 69(10) | 4.75 (1.30–17.33) | 0.02 | 0.004 | 63(10) | 3.35 (0.69–16.38) | 0.14 | 0.12 | |||
| Subtype 4 | 19(5) | 9.73 (2.32–40.75) | 0.002 | 18(5) | 5.90 (1.06–32.92) | 0.043 | |||||
|
| |||||||||||
| c) | |||||||||||
|
| |||||||||||
| Base model |
Full model |
||||||||||
| No. patients (No. events) | HR (95% CI) | p-value | Global p-valuea |
No. patients (No. events) | HR (95% CI) | p-value | Global p-valuea |
||||
|
|
|||||||||||
| BCR | |||||||||||
| Subtype 1 | 21(4) | REF | 21(4) | REF | |||||||
| Subtype 2 | 77(19) | 1.60 (0.54–4.73) | 0.39 | 73(16) | 0.84 (0.27–2.63) | 0.77 | |||||
| Subtype 3 | 97(34) | 1.93 (0.69–5.34) | 0.18 | 0.19 | 86(28) | 1.15 (0.39–3.40) | 0.81 | 0.81 | |||
| Subtype 4 | 41(8) | 1.06 (0.32–3.53) | 0.93 | 33(4) | 0.47 (0.12–1.90) | 0.29 | |||||
| Metastatic-lethal | |||||||||||
| Subtype 1 | 18(1) | REF | 18(1) | REF | |||||||
| Subtype 2 | 65(7) | 2.67 (0.32–22.23) | 0.36 | 63(6) | 1.50 (0.16–14.14) | 0.72 | |||||
| Subtype 3 | 76(13) | 3.30 (0.43–25.49) | 0.25 | 0.25 | 68(10) | 1.66 (0.20–14.02) | 0.64 | 0.59 | |||
| Subtype 4 | 35(2) | 1.46 (0.13–16.41) | 0.76 | 30(1) | 0.59 (0.04–10.08) | 0.72 | |||||
a
Global p-value is for testing association of all 4 subtypes.